HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

MannKind seeks long-awaited sales boost with inhaled insulin approval for kids

With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact in the market after struggling for more than a decade with the inhaled insulin powder.

By FiercePharma · May 30, 2026 · via FiercePharma
MannKind seeks long-awaited sales boost with inhaled insulin approval for kids

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
The WeekFierceBiotech ↗
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T …
May 30, 2026
Leadership Change, Clinical Setbacks, and an ADC Milestone in a Busy FDA Week
The WeekBriefing
Leadership Change, Clinical Setbacks, and an ADC Milestone in a Busy FDA Week
Allogene’s founding CEO steps down, Agios halts development of tebapivat, AbbVie gains approval for Decnupaz, …
May 30, 2026
STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
The WeekSTAT News ↗
STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own stra…
May 30, 2026